Literature DB >> 12827494

Combined lack of estrogen receptors alpha and beta affects vascular iNOS protein expression.

M Liang1, E Ekblad, M L Lydrup, B O Nilsson.   

Abstract

Endothelial and vascular smooth muscle cells express both estrogen receptor (ER) alpha and beta. Recent findings indicate that vascular ER beta and ER alpha may substitute for one another. Here, we investigate vascular morphology, contractility and protein expression in intact aorta from adult (4 months old) female mice lacking both ER alpha and ER beta (DERKO). The body weights were 17% higher ( P<0.01) in DERKO than in wild-type mice. Vascular morphology, investigated in paraffin sections from aorta stained with hematoxylin-eosin or van Gieson, was identical in DERKO and wild-type mice. Endothelial cells were clearly visible in aorta of both DERKO and wild-type animals. Morphometric analysis of media thickness and wall to lumen ratio using a computerized image analyzing system demonstrated no differences between the two groups of mice. The vascular expression of endothelial nitric oxide synthase (eNOS, NOS III) and inducible nitric oxide synthase (iNOS, NOS II) was investigated using Western blotting. Aorta from both DERKO and wild-type mice expressed iNOS protein, but the iNOS expression was 3 times lower ( P<0.05) in DERKO compared to wild-type mice. No difference in eNOS protein level between the two groups of animals was observed. Force responses to noradrenaline, determined either in the absence or in the presence of the nitric oxide synthase inhibitor l-NAME and the cyclo-oxygenase inhibitor indomethacin, were unaffected by the lack of functional ER alpha/ER beta. In summary, combined lack of functional ER alpha and ER beta lowers the vascular expression of iNOS but has no effects on morphology, eNOS expression, and noradrenaline sensitivity in the intact aorta.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12827494     DOI: 10.1007/s00441-003-0731-3

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  6 in total

1.  Plasma concentrations of a type II collagen-derived peptide and its nitrated form in growing Ardenner sound horses and in horses suffering from juvenile digital degenerative osteoarthropathy.

Authors:  J-Ph Lejeune; D Serteyn; M Gangl; N Schneider; G Deby-Dupont; M Deberg; Y Henrotin
Journal:  Vet Res Commun       Date:  2007-01-24       Impact factor: 2.459

Review 2.  Nitric oxide synthases and tubal ectopic pregnancies induced by Chlamydia infection: basic and clinical insights.

Authors:  Ruijin Shao; Sean X Zhang; Birgitta Weijdegård; Shien Zou; Emil Egecioglu; Anders Norström; Mats Brännström; Håkan Billig
Journal:  Mol Hum Reprod       Date:  2010-07-20       Impact factor: 4.025

3.  Differential modulation of nitric oxide synthases in aging: therapeutic opportunities.

Authors:  Stefany B A Cau; Fernando S Carneiro; Rita C Tostes
Journal:  Front Physiol       Date:  2012-06-25       Impact factor: 4.566

4.  Endothelial epidermal growth factor receptor is of minor importance for vascular and renal function and obesity-induced dysfunction in mice.

Authors:  Barbara Schreier; Christian Stern; Virginie Dubourg; Alexander Nolze; Sindy Rabe; Sigrid Mildenberger; Claudia Wickenhauser; Michael Gekle
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

5.  Distinct roles of estrogen receptor-alpha and beta in the modulation of vascular inducible nitric-oxide synthase in diabetes.

Authors:  Andrea Cignarella; Chiara Bolego; Valeria Pelosi; Clara Meda; Andrée Krust; Christian Pinna; Rosa Maria Gaion; Elisabetta Vegeto; Adriana Maggi
Journal:  J Pharmacol Exp Ther       Date:  2008-10-02       Impact factor: 4.030

6.  Knockout of vascular smooth muscle EGF receptor in a mouse model prevents obesity-induced vascular dysfunction and renal damage in vivo.

Authors:  Christian Stern; Barbara Schreier; Alexander Nolze; Sindy Rabe; Sigrid Mildenberger; Michael Gekle
Journal:  Diabetologia       Date:  2020-06-17       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.